Michael Pan
YOU?
Author Swipe
View article: The Human Cardiac “Age‐OME”: Age‐Specific Changes in Myocardial Molecular Expression
The Human Cardiac “Age‐OME”: Age‐Specific Changes in Myocardial Molecular Expression Open
Ageing is one of the most significant risk factors for heart disease; however, it is still not clear how the human heart changes with age. Taking advantage of a unique set of pre‐mortem, cryopreserved, non‐diseased human hearts, we perform…
View article: Impact of race and ethnicity on clinical outcomes and recurrence post‐ureteral reconstruction
Impact of race and ethnicity on clinical outcomes and recurrence post‐ureteral reconstruction Open
Introduction Ureteral stricture disease (UTSD) poses significant challenges in reconstructive urology, with recent advances highlighting disparities in healthcare outcomes based on race and ethnicity. This study investigates the impact of …
View article: SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID‐19: The International Study of Inflammation in COVID‐19
SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID‐19: The International Study of Inflammation in COVID‐19 Open
Severe coronavirus disease 2019 (COVID‐19) is a hyperinflammatory syndrome. The biomarkers of inflammation best suited to triage patients with COVID‐19 are unknown. We conducted a prospective multicenter observational study of adult patien…
View article: Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE‐BMT Risk Score
Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE‐BMT Risk Score Open
Background Evidence guiding the pre‐hematopoietic stem cell transplantation (HSCT) cardiovascular evaluation is limited. We sought to derive and validate a pre‐HSCT score for the cardiovascular risk stratification of HSCT candidates. Metho…
View article: Author Correction: Engineered bacterial voltage-gated sodium channel platform for cardiac gene therapy
Author Correction: Engineered bacterial voltage-gated sodium channel platform for cardiac gene therapy Open
View article: Cardiovascular Events After Hematopoietic Stem Cell Transplant
Cardiovascular Events After Hematopoietic Stem Cell Transplant Open
The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.
View article: Malnutrition in heart failure with preserved ejection fraction
Malnutrition in heart failure with preserved ejection fraction Open
Background Malnutrition may be an important geriatric condition in adults with heart failure with preserved ejection fraction (HFpEF), but studies on its prevalence and associated clinical outcomes are limited. The aim of this study was to…
View article: Supplemental Figure S1 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S1 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Therapeutic efficacy of αTRP1 combined with two doses of cyclophosphamide (CY) in established melanoma.
View article: Supplemental Figure Legends from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure Legends from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Supplemental Figure Legends
View article: Supplemental Figure S5 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S5 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Therapy with αTRP1+CY can activate T cells against melanoma.
View article: Supplemental Methods from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Methods from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Supplemental Methods
View article: Data from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Data from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
We sought to define cellular immune mechanisms of synergy between tumor-antigen–targeted monoclonal antibodies and chemotherapy. Established B16 melanoma in mice was treated with cytotoxic doses of cyclophosphamide in combination with an a…
View article: Supplemental Figure S4 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S4 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Absence of CD90+ populations in F4/80+ CD11b+ macrophages.
View article: Supplemental Figure S2 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S2 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Depletion of NKp46+ (A), CD90+ (B), and CD8+ (C) cells.Gating strategy to identify macrophage and MDSC populations.
View article: Supplemental Figure S4 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S4 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Absence of CD90+ populations in F4/80+ CD11b+ macrophages.
View article: Supplemental Figure S3 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S3 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Gating strategy to identify macrophage and MDSC populations.
View article: Supplemental Figure S5 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S5 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Therapy with αTRP1+CY can activate T cells against melanoma.
View article: Supplemental Figure S3 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S3 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Gating strategy to identify macrophage and MDSC populations.
View article: Supplemental Figure S1 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S1 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Therapeutic efficacy of αTRP1 combined with two doses of cyclophosphamide (CY) in established melanoma.
View article: Supplemental Figure Legends from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure Legends from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Supplemental Figure Legends
View article: Supplemental Methods from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Methods from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Supplemental Methods
View article: Data from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Data from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
We sought to define cellular immune mechanisms of synergy between tumor-antigen–targeted monoclonal antibodies and chemotherapy. Established B16 melanoma in mice was treated with cytotoxic doses of cyclophosphamide in combination with an a…
View article: Supplemental Figure S2 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy
Supplemental Figure S2 from Requirement for Innate Immunity and CD90<sup>+</sup> NK1.1<sup>−</sup> Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy Open
Depletion of NKp46+ (A), CD90+ (B), and CD8+ (C) cells.Gating strategy to identify macrophage and MDSC populations.
View article: Common FUE Graft Harvesting Problems and Solutions
Common FUE Graft Harvesting Problems and Solutions Open
Technological innovation in follicular unit excision (FUE) has made graft harvesting more efficient than ever, allowing surgeons to increase the number of grafts they can obtain in a single session. Factors such as scalp quality and follic…
View article: Relationship Between Preexisting Cardiovascular Disease and Death and Cardiovascular Outcomes in Critically Ill Patients With COVID-19
Relationship Between Preexisting Cardiovascular Disease and Death and Cardiovascular Outcomes in Critically Ill Patients With COVID-19 Open
Background: Preexisting cardiovascular disease (CVD) is perceived as a risk factor for poor outcomes in patients with COVID-19. We sought to determine whether CVD is associated with in-hospital death and cardiovascular events in critically…
View article: Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19 Open
Background Venous thromboembolism (VTE) contributes significantly to COVID‐19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation. Levels of soluble urokinase plasminogen activator receptor (…
View article: Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19
Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19 Open
Objective: Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that are unclear. Research Design and Methods: We leveraged The International Study of Inflammation in COVID-…
View article: Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19
Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19 Open
OBJECTIVE Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that are unclear. RESEARCH DESIGN AND METHODS We leveraged the International Study of Inflammation in COVID-19 (ISIC), a mul…
View article: Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19
Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19 Open
Objective: Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that are unclear. Research Design and Methods: We leveraged The International Study of Inflammation in COVID-…
View article: Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19 Open
Background Use of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) is thought to affect COVID‐19 through modulating levels of angiotensin‐converting enzyme 2, the cell entry receptor for SARS‐CoV2. We s…